共 247 条
[11]
Logothetis C(2013)A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human αν integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate cancer Ann Oncol 24 329-336
[12]
Gravis G(2011)The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials BMJ 343 d5928-3200
[13]
Beer TM(2016)Differential effect on bone lesions of targeting integrins: randomized phase II trial of abituzumab in patients with metastatic castration-resistant prostate cancer Clin Cancer Res 22 3192-784
[14]
Armstrong AJ(2015)The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations Ann Intern Med 162 777-973
[15]
Rathkopf D(2010)Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized phase II trial BJU Int 106 966-1540
[16]
Loriot Y(2012)Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401 J Clin Oncol 30 1534-712
[17]
Sternberg CN(2014)Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial Lancet Oncol 15 700-82
[18]
Higano CS(2015)Effects of fluroquinolones in newly diagnosed, sputum-positive tuberculosis therapy: a systematic review and network meta-analysis PLoS One 10 e0145066-5718
[19]
Cathomas R(2014)Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer J Clin Oncol 32 76-2106
[20]
Crabb SJ(2012)Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone Cancer 118 5709-425